MIA leads world-class skin tumour pathology conference
14 February 2020
World-leading skin cancer experts, headed by Co-Medical Director of Melanoma Institute Australia Professor Richard Scolyer, will converge on The University of Sydney’s Charles Perkins Centre this weekend to instruct a sold-out, two-day course on ‘Pigmented Lesions and Other Hot Topics in Dermatopathology’.
Attendees will also hear from two international melanoma experts across the breadth of the program - Professor Klaus Busam, Director of Dermatopathology at Memorial Sloan Kettering Cancer Centre, New York, and Professor Pedram Gerami, Professor of Dermatology at Northwestern University, Illinois.
MIA clinicians and researchers will provide a wealth of home-grown expertise with talks from epidemiologist Professor Anne Cust, pathologists Dr Peter Ferguson and Dr Robert Rawson, world-renowned melanoma and surgical oncologist Professor John Thompson, and Co-Medical Director of MIA Professor Georgina Long.
The course aims to provide international attendees with the latest in skin tumour pathology, discussing current best practice and new tests, along with highlighting the integration of clinical and genomic information for diagnosis, prognosis and treatment selection. The course will end with detailed examination of high-value educational cases to consolidate two days worth of world-class learnings.
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Congratulations are in order for two of our talented researchers.
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.
We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.
Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.
We value your privacy and want you to be familiar with how we collect, use and disclose your information.
Melanoma Institute Australia has partnered with IBM Research in Australia to help further advance melanoma identification using cognitive technology.
CEO Carole Renouf chats to senior clinicians and researchers as part of our "4 Questions With..." short video series.
MIA's 'Stop the Spread' campaign has been shortlisted in the 2016 Cannes Lions International Festival of Creativity.